 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Zoetis Inc. (ZTS) discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally.
It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.
It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products.
In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists.
Shares are heading higher in an upward trading channel. The lower boundary of the said channel coincides with the stock's 50-day moving average. We expect shares to see a rebond here.
52-Weeks Trading Range: $52.25 - $85.73
Entry Point: $81.00
Stop Loss: $76.85
Target Price: $89.10
ZTS closed at $85.56
